Literature DB >> 7587821

Effect of splenectomy on hepatic metastasis of colon carcinoma and natural killer activity in the liver.

Y Shiratori1, T Kawase, R Nakata, M Tanaka, Y Hikiba, K Okano, M Matsumura, Y Niwa, Y Komatsu, S Shiina.   

Abstract

We have previously demonstrated that administration of killed streptococcal preparation (OK432), a biological modifier, increased the number of asialo GM1-positive cells in the liver, enhanced NK activity of hepatic mononuclear cells, and reduced the number of hepatic metastases of colon 38 adenocarcinoma that were inoculated into the superior mesenteric vein of C57BL/6 strain mice. In the present study, to clarify the role of the spleen in immune surveillance of the liver, the effect of splenectomy on hepatic metastasis of colon carcinoma and on hepatic NK activity has been examined. The number of hepatic metastasis increased in the splenectomized mice, compared with that in sham-operated mice. Administration of OK432 increased the number of asialo GM1-positive cells in the liver and enhanced NK activity of hepatic mononuclear cells in both groups, but NK activity of hepatic mononuclear cells in the splenectomized mice was less than that of the sham-operated mice. An enhanced NK activity of these cells was abolished by treatment with anti-asialo-GM1 antibody plus complement in vitro. Interleukin-2 mRNA expression was increased in the spleen 2 hr after OK432 administration and persisted until 8 hr, but was scarcely noted in the liver. On the other hand, NK activity of hepatic mononuclear cells in the asialo GM1-positive cell-depleted (previous administration of antiserum against asialo GM1) mice was enhanced after OK432 administration in the sham operated and splenectomized mice, but an enhanced NK activity in these mice was only partially or not at all abolished by treatment with anti-asialo GM1 antibody plus complement in vitro, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587821     DOI: 10.1007/BF02063244

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  36 in total

1.  The pit cell: description of a new type of cell occurring in rat liver sinusoids and peripheral blood.

Authors:  E Wisse; J M van't Noordende; J van der Meulen; W T Daems
Journal:  Cell Tissue Res       Date:  1976-10-19       Impact factor: 5.249

2.  Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine.

Authors:  N Thurnherr; E E Deschner; E H Stonehill; M Lipkin
Journal:  Cancer Res       Date:  1973-05       Impact factor: 12.701

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 4.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

5.  Inhibition of hepatic metastasis of colon carcinoma by asialo GM1--positive cells in the liver.

Authors:  Y Shiratori; R Nakata; K Okano; Y Komatsu; S Shiina; T Kawase; T Sugimoto; M Omata; M Tanaka
Journal:  Hepatology       Date:  1992-08       Impact factor: 17.425

6.  Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid.

Authors:  L L Thomsen; L M Ching; B C Baguley
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

7.  Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.

Authors:  S Gallinger; D W Hoskin; J B Mullen; A H Wong; J C Roder
Journal:  Cancer Res       Date:  1990-04-15       Impact factor: 12.701

8.  Identification and percentage frequency of isolated non-parenchymal liver cells (NPLC) in the mouse.

Authors:  N Freudenberg; J Schalk; C Galanos; T Katschinski; O Datz; U Pein; M A Freudenberg
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

9.  Immuno-electron microscopic characterization of large granular lymphocytes (natural killer cells) from rat liver.

Authors:  L Bouwens; E Wisse
Journal:  Eur J Immunol       Date:  1987-10       Impact factor: 5.532

10.  Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432.

Authors:  K Oshimi; S Kano; F Takaku; K Okumura
Journal:  J Natl Cancer Inst       Date:  1980-12       Impact factor: 13.506

View more
  5 in total

1.  Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.

Authors:  Liran Levy; Inbal Mishalian; Rachel Bayuch; Lida Zolotarov; Janna Michaeli; Zvi G Fridlender
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

2.  Prognoses of advanced esophago-gastric junction cancer may be modified by thoracotomy and splenectomy.

Authors:  Kei Hosoda; Keishi Yamashita; Harukazu Tsuruta; Hiromitsu Moriya; Hiroaki Mieno; Akira Ema; Marie Washio; Masahiko Watanabe
Journal:  Oncol Lett       Date:  2017-11-17       Impact factor: 2.967

3.  Role of sialylglycoconjugate(s) in the initial phase of metastasis of liver-metastatic RAW117 lymphoma cells.

Authors:  H Kikkawa; D Miyamoto; H Imafuku; C Koike; Y Suzuki; S Okada; H Tsukada; T Irimura; N Oku
Journal:  Jpn J Cancer Res       Date:  1998-12

4.  Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model.

Authors:  Ho Kyoung Hwang; Takashi Murakami; Tasuku Kiyuna; Se Hoon Kim; Sung Hwan Lee; Chang Moo Kang; Robert M Hoffman; Michael Bouvet
Journal:  Oncotarget       Date:  2017-09-28

5.  Local targeted therapy of liver metastasis from colon cancer by galactosylated liposome encapsulated with doxorubicin.

Authors:  Chen Zhao; Qiang Feng; Zengpei Dou; Wei Yuan; Chenguang Sui; Xinghua Zhang; Guimin Xia; Hongfang Sun; Jie Ma
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.